Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. Kavanagh (London, United Kingdom), C. Roxas (London, United Kingdom), L. Green (London, United Kingdom), M. Fernandes (London, United Kingdom), L. Thomson (London, United Kingdom), V. Payne (London, United Kingdom), A. Hearn (London, United Kingdom), B. Kent (London, United Kingdom), G. D'Ancona (London, United Kingdom), J. Dhariwal (London, United Kingdom), A. Nanzer (London, United Kingdom), D. Jackson (London, United Kingdom). Super-responder analysis and real-world one year effectiveness of benralizumab in severe eosinophilic asthma. 2261

Member's Comments

No comment yet.

Related content which might interest you: Real-life effectiveness of anti-IL-5(-receptor) antibody treatment in patients with severe eosinophilic asthma Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 Mepolizumab in real-life treatment of severe eosinophilic asthma Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Real-world effectiveness of reslizumab for severe eosinophilic asthma (SEA) Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Real-life impact of weight in severe eosinophilic asthma patients treated with benralizumab Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies Year: 2021 Real-life experience with mepolizumab in the French early access program for severe eosinophilic asthma Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 Real-life treatment of severe eosinophilic asthma with mepolizumab Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Mepolizumab is effective in severe eosinophilic asthmatics: an Austrian real-life study. Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 A weight-based exacerbation dose-response analysis of mepolizumab in severe asthma with eosinophilic phenotype Source: International Congress 2016 – Asthma management Year: 2016 Predictor of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Response to benralizumab in severe eosinophilic asthma after intermediate-to-poor response to mepolizumab : a retrospective study. Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020 Discontinuation of benralizumab in Canadian patients with severe eosinophilic asthma Source: ERJ Open Res, 7 (4) 00465-2021; 10.1183/23120541.00465-2021 Year: 2021 Continued long-term mepolizumab in severe eosinophilic asthma protects from asthma worsening versus stopping mepolizumab: COMET trial Source: Virtual Congress 2020 – Recent innovations regarding the mechanisms and treatments of asthma Year: 2020 Cost-effectiveness of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma Source: Virtual Congress 2020 – How do different treatment strategies translate into costs Year: 2020 Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study) Source: Eur Respir J, 59 (1) 2100396; 10.1183/13993003.00396-2021 Year: 2022 Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme Source: Eur Respir J, 55 (6) 1902345; 10.1183/13993003.02345-2019 Year: 2020 Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 The relationship between severe asthma eosinophilic phenotypes and the clinical response to benralizumab at 16 weeks Source: International Congress 2019 – Clinical studies of asthma treatments Year: 2019 Omalizumab in severe uncontrolled asthma: two and a half year clinical experience Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Omalizumab is effective in patients with severe persistent allergic asthma in a real-life setting irrespective of age Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Which patients should be treated with anti-IgE? Source: Eur Respir Rev 2007; 16: 85-87 Year: 2007